English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: The purpose of this study was to investigate the prognostic factors of stereotactic body radiother‐ apy (SBRT) for stage I non-small-cell lung cancer (NSCLC) to improve outcomes. Materials and methods: Between 2008 and 2016, 71 patients with medically inoperable stage I NSCLC were treated at our hospital with SBRT (48–55 Gy in 4–5 fractions for peripheral lesions or 60–64 Gy in 8–10 frac‐ tions for central lesions). Survival outcomes were analyzed using Kaplan-Meier and cumulative incidence meth‐ ods. Factors including sex, age, tumor location, tumor size, BED (biologically effective dose) 10, and maximum standardized uptake value (SUVmax) were evaluated with regard to overall survival (OS) and disease-specific survival (DSS) using Cox proportional hazard regression. Results: The median follow-up duration of surviving patients was 33 months (range, 6–81 months). Two-year OS and DSS were 78.5% and 91.5%, respectively. Two-year cumulative local recurrence rate, regional recur‐ rence rate, and distant metastasis rate were 6.8%, 10.9%, and 7.3%, respectively. Multivariate analysis revealed that BED10 and SUVmax were prognostic factors for DSS. Conclusion: Lower BED10 and higher SUVmax were predictors of significantly worse DSS. A higher SUV‐ max may be considered for intensive treatment to improve outcomes.

journal of st. marianna university

Prognostic Factors for Overall and Disease-specific Survival of Stage I Non-Small-Cell Lung Cancer after Stereotactic Body Radiotherapy: A Retrospective Analysis